---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-032948"
form_type: "8-K"
ticker: "PLUR"
cik: "0001158780"
company_name: "Pluri Inc."
filed_at: "2025-04-17T23:59:59+00:00"
generated_at: "2026-05-23T11:33:53.191575+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Pluri's subsidiary loses $4.2M NIAID contract for PLX-R18 H-ARS therapy; termination for convenience effective April 15

## Summary
- Pluri Biotech Ltd. received termination notice from NIAID for a $4.2M contract awarded July 2023 to develop PLX-R18 for Hematopoietic Acute Radiation Syndrome.
- Termination effective April 15, 2025, for the government's convenience; Pluri links it to broader federal budgetary adjustments affecting NIH.
- Contract involved collaboration with AFRRI and USUHS; company is monitoring potential implications for other programs.

## SEC filing metadata
- accession: 0001213900-25-032948
- form_type: 8-K
- ticker: PLUR
- cik: 0001158780
- company_name: Pluri Inc.
- filed_at: 2025-04-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/0001213900-25-032948-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/ea0238672-8k_pluri.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-032948
- JSON: https://secwatch.observer/filing/0001213900-25-032948.json
- Plain text: https://secwatch.observer/filing/0001213900-25-032948.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.